Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 34-38

  Wu, Zhiwei ^a,d   Zhang, Xiang Yang ^b,c   Wang, Huanhuan ^a   Tang, Wei ^d   Xia, Yu ^a   Zhang, FeiXue ^d   Liu, Jiahong ^d   Fu, Ye ^a   Hu, Jianjun ^a   Chen, Yuanling ^d   Liu, Linjing ^d   Chen, Da Chun ^c   Xiu, Mei Hong ^c   Kosten, Thomas R ^b   He, Jincai ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BEIJING HUILONGGUAN HOSPITAL   (China)

^d Zhejiang Provincial Clinical Research Center for Mental Disorder   (China)

Author keywords

Free radical; Oxidative stress; Psychopathology; Schizophrenia; Superoxide dismutase

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 82555190944     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.018     Document Type: Article

References (52)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neurol psychopharmacol Biol Psychiatry 2002, 26:995-1005.
2. Bai O., Wei Z., Lu W., Bowen R., Keegan D., Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002, 69:278-283.
3. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13:544-556.
4. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(1):155-159.
5. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35(3):878-893.
6. Bolzán A.D., Bianchi M.S., Bianchi N.O. Superoxide dismutase, catalase and glutathione peroxidase activities in human blood: influence of sex, age and cigarette smoking. Clin Biochem 1997, 30(6):449-454.
7. Buckley P.F., Evans D. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes. Postgrad Med Spec 2006, 5-19.
8. Buckman T.D., Kling A.S., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31:1-14.
9. Cadet J.L., Perumal A.S. Chronic treatment with Prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990, 28:738-740.
10. Ceballos-Picot I., Trivier J.M., Nicole A., Sinet P.M., Thevenin M. Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes. Clin Chem 1992, 38(1):66-70.
11. Chiou J.F., Hu M.L. Elevated lipid peroxidation and disturbed antioxidant enzyme activities in plasma and erythrocytes of patients with uterine cervicitis and myoma. Clin Biochem 1999, 32:189-192.
12. Chittiprol S., Venkatasubramanian G., Neelakantachar N., Babu S.V., Reddy N.A., Shetty K.T., et al. Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res 2010, 44(5):310-313.
13. Dadheech G., Mishra S., Gautam S., Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008, 50(1):16-20.
14. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
15. Dietrich-Muszalska A., Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci 2010, 64(5):469-475.
16. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(3):512-515.
17. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
18. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
19. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-mediated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
20. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1677-1681.
21. Li X.F., Zheng Y.L., Xiu M.H., Chen da C., Kosten T.R., Zhang X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(4):1064-1067.
22. Lohr J.B. Oxygen radicals and neuropsychiatric illness, some speculations. Arch Gen Psychiatry 1991, 48:1097-1106.
23. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165.
24. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
25. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19:1-17.
26. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R., Mahadik J. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43:674-679.
27. McCreadie R.G., Macdonald E., Wiles D., Campbell G., Pateson J.R. The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects. Br J Psychiatry 1995, 167:1-8.
28. Mukherjee S., Mahadik S.P., Scheefer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26.
29. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
30. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984, 142:290-296.
31. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479(3):317-320.
32. Pazvantoglu O., Selek S., Okay I.T., Sengul C., Karabekiroglu K., Dilbaz N., et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009, 63(5):693-700.
33. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(7):1178-1183.
34. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
35. Reddy R.D., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412.
36. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996, 55:33-43.
37. Reddy R.D., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
38. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(6):1164-1169.
39. Saraymen R., Kilic E., Yazar S., Cetin M. Influence of sex and age on the activity of antioxidant enzymes of polymorphonuclear leukocytes in healthy subjects. Yonsei Med J 2003, 44(1):9-14.
40. Shimoda-Matsubayashi S., Hattori T., Matsumine H., Shinohara A., Yoritaka A., Mori H., et al. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonismin comparison with Parkinson's disease and control. Neurology 1997, 49:1257-1262.
41. Smesny S., Kinder D., Willhardt I., Rosburg T., Lasch J., Berger G., et al. Increased calcium-independent phospholipase A2 activity in first but not in multi episode chronic schizophrenia. Biol Psychiatry 2005, 57(4):399-405.
42. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998, 155:1207-1213.
43. Ustundag B., Atmaca M., Kirtas O., Selek S., Metin K., Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:458-464.
44. Virit O., Altindag A., Yumru M., Dalkilic A., Savas H.A., Selek S., et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60(2):87-93.
45. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal Jan 2 2011, [Epub ahead of print].
46. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
47. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
48. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85-88.
49. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62:245-250.
50. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
51. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study. J Clin Psychopharmacol 2006, 26(1):103-105.
52. Zhang Z., Zhang X., Hou G., Sha W., Reynolds G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002, 36(5):317-324.